TORC resTORbio Inc.

6.91
-0.09  -1%
Previous Close 7
Open 7.04
Price To Book 1.97
Market Cap 250,291,671
Shares 36,221,660
Volume 214,487
Short Ratio
Av. Daily Volume 113,613
Stock charts supplied by TradingView

NewsSee all news

  1. AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

    WALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG") today announced that it has entered into a settlement agreement with Caligan Partners LP ("Caligan"). As part of this

  2. resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

    BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

  3. resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

  4. resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019

    BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data due early-1Q 2020.
RTB101 - PROTECTOR 1
Respiratory Tract Infections
Phase 2 data due 2020.
RTB101
Parkinson's disease
Phase 3 trial to commence 4Q 2019 with data due mid-2020.
RTB101 - PROTECTOR 2
Respiratory Tract Infections
Phase 2b data presented at IDSA October 3, 2019.
RTB101
Respiratory Tract Infections

Latest News

  1. AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

    WALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG") today announced that it has entered into a settlement agreement with Caligan Partners LP ("Caligan"). As part of this

  2. resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

    BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

  3. resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

  4. resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019

    BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related